Powered by: Motilal Oswal
13/10/2021 11:13:24 AM | Source: ICICI Direct
Hold Cadila Healthcare Ltd For Target Rs.583 - ICICI Direct
News By Tags | #872 #494 #3961 #642 #1302
Hold Cadila Healthcare Ltd For Target Rs.583 - ICICI Direct

Indian shines but US slowdown persists…

About the stock: Cadila is a leading pharma company with a presence across the value chain of innovating, manufacturing, marketing & selling finished dosage human formulations (generics, branded generics & specialty formulations, including biosimilars & vaccines), APIs, animal healthcare & consumer wellness products.

* It has a global presence and sells its products in the US, India, Europe & emerging markets including countries in LatAm, Asia Pacific & Africa.

* Cadila is the fourth largest pharma company in India with 14 brands among Top 300 pharma brands in India & nine with | 100 crore+ sales.

 

Q1FY22 Results: Cadila reported steady Q1FY22 results.

* Sales were up 14.5% YoY to | 4025.4 crore

* EBITDA in Q1FY22 was at | 933 crore, up 35% YoY with margins at 23.2%

* Consequent adjusted PAT was at | 564.8 crore (up 71.8% YoY)

 

What should investors do?

Cadila’s share price has grown by ~1.6x over the past five years (from ~| 352 in July 2016 to ~| 586 levels in July 2021).

* We maintain HOLD rating

Target Price and Valuation: We value Cadila at | 583 (base business of | 483 at 22x P/E on FY23E EPS + NPV of | 99.9 for vaccine & gRevlimid opportunity).

 

Key triggers for future price performance:

* Cadila plans to venture into complex injectable in US. However, it is likely to provide meaningful traction only from FY23-24 onwards.

* US pipeline of 412 filed ANDAs, 317 final approvals is promising but cGMP issues at Moraiya, slowdown in base are main near term headwinds

* India formulations business is likely to stabilise as the company has optically initiated restructuring of business by rationalising slow moving SKUs

 

Alternate Stock Idea: Apart from Cadila, in our healthcare coverage we like Cipla

* Cipla is a global pharma company with over 1,500+ products in 65 therapeutic categories, with over 50 dosage forms.

* BUY with a target price of | 1205

 

To Read Complete Report & Disclaimer Click Here

 

https://secure.icicidirect.com/Content/StaticData/Disclaimer.html

 

Above views are of the author and not of the website kindly read disclaimer

Disclaimer: The content of this article is for informational purposes only and should not be considered financial or investment advice. Investments in financial markets are subject to market risks, and past performance is not indicative of future results. Readers are strongly advised to consult a licensed financial expert or advisor for tailored advice before making any investment decisions. The data and information presented in this article may not be accurate, comprehensive, or up-to-date. Readers should not rely solely on the content of this article for any current or future financial references. To Read Complete Disclaimer Click Here